Genocea Biosciences, a Cambridge, MA-based vaccine developer, said today it has obtained licenses to 25 pending or issued patents on herpes simplex type 2 antigens from the University of Washington and Fred Hutchinson Cancer Research Center. Those antigens could be used as the basis for a new immune-boosting treatment for genital herpes. Genocea CEO Staph Bakali described the company’s plans to treat herpes in an interview with Xconomy in December.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
